Infectious Diseases and Antimicrobials
Congenital and Neonatal Viral Infections
- Congenital Cytomegalovirus (CMV): ((((NINF001)) · ((NINF012)) · ((NINF013)))):
- Diagnostic Gold Standard: : Urine or saliva PCR/culture is preferred over blood due to higher sensitivity; blood PCR is highly specific but less sensitive ((NINF001)). Infection is defined within the first 3 weeks of life ((NINF001)).
- Treatment: : Intravenous ganciclovir 6 mg/kg/dose every 12 hours (indicated for symptomatic CNS disease to improve hearing and neurodevelopmental outcomes), transitioning to oral valganciclovir once enteral feeds are tolerated ((NINF012)).
- Adverse Effects: : Neutropenia and transaminitis; requires serial CBC and ALT monitoring (((NINF012)) · ((NINF016))).
- Counseling & Prevention: : Animal studies show potential reproductive toxicity (e.g., Leydig cell tumors) ((NINF002)). CDC does not recommend restricting contact with toddlers for occupationally exposed pregnant women, but emphasizes strict hand hygiene and avoiding saliva contact ((NINF013)). Routine screening is not adopted ((NINF013)).
- Neonatal Herpes Simplex Virus (HSV): ((((NINF003)) · ((NINF014)) · ((NINF015)) · ((NINF016)) · ((NINF017)) · ((NINF018)) · ((NINF019)))):
- Disseminated Disease Markers: : Serum ALT >2 times the upper limit of normal is suggestive of hepatic involvement ((NINF003)).
- Management by Maternal Presentation: : - Recurrent lesions / Prior history: Lower transmission risk due to maternal antibodies. Initial evaluation requires HSV surface cultures/PCR and HSV blood PCR ((NINF014)). Vaginal delivery is permitted if no lesions or prodromal symptoms are present at labor ((NINF018)). Suppressive acyclovir near term helps facilitate vaginal delivery ((NINF018)). - Primary maternal infection near delivery: High transmission risk, lack of maternal antibodies. Requires pre-emptive IV acyclovir for 10 days even if initial PCR/surface cultures are negative ((NINF015)).
- Clinical Manifestations: : Skin, Eye, and Mouth (SEM) disease accounts for ~50% of cases; vesicles occur in ~90% of cases (not 50-60%) ((NINF017)). Keratoconjunctivitis can progress to chorioretinitis, cataracts, and retinopathy ((NINF017)).
- Infection Control Exceptions: : Nursery personnel with herpetic whitlow must not care for newborns because transmission occurs despite glove use ((NINF019)). Conversely, healthcare workers with orolabial HSV may work if masked, and mothers with breast lesions may breastfeed if lesions are covered ((NINF019)).
- Monitoring: : Requires absolute neutrophil count (ANC) monitoring during both IV ganciclovir (plus ALT) and oral acyclovir suppression therapy ((NINF016)).
- Hepatitis C Virus (HCV): ((((NINF004)) · ((NINF005)) · ((NINF006)) · ((NINF007)) · ((NINF024)))):
- Diagnostics & Antivirals: : Among term-approved ARVs (zidovudine, lamivudine, emtricitabine, nevirapine, raltegravir), only zidovudine has been adequately studied in preterm neonates ((NINF004)). HCV ELISA detects antibodies against c100-3, c22-3, and c33c, while the Radioimmunoblot Assay (RIBA) uniquely detects 5-5-1 alongside these three ((NINF005)). Hepatitis G virus (HGV) is diagnosed via HGV RNA PCR ((NINF007)).
- Post-Exposure & Follow-up: : IVIG provides no benefit for HCV needle-stick or neonatal exposure because anti-HCV antibodies are excluded from pooled lots ((NINF006)). Excluded infants are definitively tested with anti-HCV antibody at ≥18 months of age ((NINF024)).
- Other Neonatal Viral Infections & Teratogens: ((((NINF008)) · ((NINF009)) · ((NINF010)) · ((NINF011)) · ((NINF020)) · ((NINF021)) · ((NINF022)) · ((NINF023)) · ((NINF025)))):
- Human Parechovirus (HPeV): : HPeV-3 causes severe disease in neonates <2 months, including meningoencephalitis, white matter injury mimicking HIE, and palmoplantar rash ((NINF008)).
- Zika Virus: : Associated with fetal loss, microcephaly, arthrogryposis, and chorioretinal atrophy; pigmentary retinopathy is not a core feature ((NINF009)).
- SARS-CoV-2: : Most neonatal infections occur via horizontal transmission from caregivers postnatally, rather than transplacentally ((NINF010)).
- Congenital Rubella: : Presents with cataracts, PDA (machinery murmur), purpura, hepatosplenomegaly, and microcephaly; confirmed via urine culture ((NINF011)).
- Parvovirus B19: : Causes severe fetal anemia, hydrops, and myocarditis via erythroid precursor infection, but is unlikely to cause structural congenital malformations after 20 weeks; maternal infection is not an indication for termination ((NINF020)).
- HIV in Infants & Care: : Mothers living with HIV who choose not to breastfeed should use exclusive replacement feeding only if AFASS criteria are met, using a katori-spoon (avoid bottles) ((NINF021)). Low-risk neonates receive twice-daily zidovudine for 4–6 weeks ((NINF022)). HIV encephalopathy characteristically presents with loss of developmental milestones and cognitive decline ((NINF023)).
- Chikungunya: : Presents with neonatal fever, irritability, rash, joint swelling, and a pathognomonic brownish nasal pigmentation (CHIK sign) during recovery ((NINF025)).
- (A) Blood testing is more sensitive than urine testing because viremia is universal at birth
- (B) Detection of CMV in blood is highly sensitive, whereas urine and saliva testing are primarily confirmatory
- (C) Detection of CMV in blood is highly specific, but urine and saliva testing have greater sensitivity
- (D) Detection of CMV in blood is highly sensitive, but urine and saliva testing have greater specificity
💡 Click to Reveal Answer & Nelson Rationale
Congenital CMV infection should be suspected in infants with typical findings such as microcephaly, petechiae, hepatosplenomegaly, thrombocytopenia, sensorineural hearing loss, or intracranial calcifications. Suspicion should also arise when there is a maternal history of seroconversion, mononucleosis-like febrile illness during pregnancy, or prenatal ultrasonographic findings such as echogenic bowel or intracranial calcifications. Diagnosis is established when CMV is identified in amniotic fluid or in the infant’s urine, saliva, blood, or respiratory secretions. Infection is classified as congenital when CMV is detected within the first 3 weeks of life, whereas a negative test during the first 3 weeks followed by positivity after 4 weeks suggests peripartum or postnatal infection. Blood is often the earliest specimen to become positive and detection of CMV in neonatal blood is highly specific for congenital infection. However, not all congenitally infected infants are viremic at birth, which limits the sensitivity of blood testing. Therefore, detection of CMV shedding in urine or saliva provides the highest sensitivity for diagnosis. A negative blood test cannot rule out congenital CMV infection, whereas a negative urine or saliva test in an untreated infant symptomatic for more than 4 weeks strongly argues against infection. This distinction between sensitivity and specificity is a high-yield conceptual point.
- (A) Leydig cell tumor
- (B) Sertoli cell tumor
- (C) Seminoma
- (D) Yolk sac tumor
💡 Click to Reveal Answer & Nelson Rationale
Ganciclovir is used in selected infants with symptomatic congenital CMV infection because increasing evidence suggests that antiviral therapy can improve hearing outcomes and long-term neurodevelopmental prognosis. However, families should be informed about the potential long-term toxicities associated with treatment. Animal studies using pharmacologic doses of ganciclovir demonstrated reproductive toxicity, including testicular atrophy and gonadal tumors. Among the options listed, the correct option is the Leydig cell tumor. Leydig cell tumors arise from the interstitial Leydig cells of the testis. Although the clinical significance of these findings in humans remains uncertain, these observations are important during parental counseling and risk-benefit discussions before initiating therapy.
- (A) Serum ALT >1.5 times the upper limit of normal
- (B) Serum ALT >2 times the upper limit of normal
- (C) Serum ALT >3 times the upper limit of normal
- (D) Serum ALT >5 times the upper limit of normal
💡 Click to Reveal Answer & Nelson Rationale
Disseminated neonatal HSV infection is a severe multisystem disease that frequently involves the liver and may present with a sepsis-like illness, respiratory distress, coagulopathy, thrombocytopenia, hepatitis, and shock. Hepatic involvement is an important clue to the diagnosis, and serum ALT forms part of the evaluation of infants with suspected disseminated HSV infection. Serum ALT values more than two times the upper normal limit may be considered suggestive of disseminated HSV disease and should prompt further diagnostic evaluation and initiation of antiviral therapy when clinically indicated.
- (A) Among antiretroviral drugs approved for use in term newborns, both zidovudine and lamivudine have been adequately studied in preterm neonates
- (B) FDA approval for use in term newborns implies adequate safety and pharmacokinetic data in preterm neonates
- (C) Zidovudine is the only antiretroviral drug among those approved for term newborns that has been adequately studied in preterm neonates
- (D) Raltegravir is preferred over zidovudine in preterm neonates because of superior pharmacokinetic data in premature infants
💡 Click to Reveal Answer & Nelson Rationale
The US FDA has approved zidovudine, lamivudine, emtricitabine, nevirapine, and raltegravir for use in term newborns. However, approval for term infants should not be interpreted as evidence of adequate study in premature infants. Among these agents, only zidovudine has been adequately studied in preterm neonates. This distinction is important because pharmacokinetics, drug metabolism, and toxicity profiles may differ substantially between term and preterm infants.
- (A) c100-3
- (B) c22-3
- (C) c33c
- (D) 5-5-1
💡 Click to Reveal Answer & Nelson Rationale
The ELISA for HCV detects antibodies against three viral proteins: c100-3, c22-3, and c33c. This assay may detect infection as early as 2 weeks after exposure. The radioimmunoblot assay (RIBA) has even greater sensitivity and detects antibodies against the same three antigens identified by ELISA (c100-3, c22-3, and c33c) as well as an additional antigen, 5-5-1.
- (A) IVIG should be administered because pooled immunoglobulin preparations contain protective anti-HCV antibodies
- (B) IVIG should be administered within 72 hours of exposure to reduce the risk of chronic HCV infection
- (C) IVIG is recommended only for infants exposed to HCV but not for healthcare workers with needle-stick exposure
- (D) IVIG is not expected to provide benefit because products containing anti-HCV antibodies are excluded from immunoglobulin lots
💡 Click to Reveal Answer & Nelson Rationale
There is no benefit expected from IVIG administration either to an HCV-exposed infant or to an individual with needle-stick exposure. The reason is that products containing anti-HCV antibodies are excluded from immunoglobulin lots, eliminating any meaningful passive protective effect. Therefore, IVIG is not recommended as post-exposure prophylaxis for HCV exposure.
- (A) Anti-HGV IgM ELISA
- (B) Radioimmunoblot assay (RIBA)
- (C) HGV RNA PCR
- (D) HGV viral culture
💡 Click to Reveal Answer & Nelson Rationale
Hepatitis G virus (HGV) shares approximately 27% homology with HCV and is frequently associated with coinfection with HBV or HCV, suggesting common routes of transmission such as transfusion or organ transplantation. Transplacental transmission is probably rare and may be associated with higher maternal viral loads. HGV is diagnosed by RNA PCR in research settings. There is currently no specific treatment or prophylactic therapy available.
- (A) Human parechovirus type 1
- (B) Human parechovirus type 2
- (C) Human parechovirus type 3
- (D) Human parechovirus type 6
💡 Click to Reveal Answer & Nelson Rationale
Human parechoviruses belong to the Picornaviridae family and were previously classified as enteroviruses. They are recognized causes of infection in neonates and young infants. Among the various types, human parechovirus type 3 (HPeV-3) is particularly important because it is associated with severe disease in neonates and young infants, **including:** Meningoencephalitis Significant white matter injury mimicking hypoxic-ischemic encephalopathy Prolonged fever Palmoplantar erythematous rash Myocarditis HPeV-3 is also implicated in nosocomial outbreaks in premature nurseries and is an important cause of meningoencephalitis in infants younger than 2 months.
- (A) Fetal loss
- (B) Arthrogryposis
- (C) Chorioretinal atrophy
- (D) Pigmentary retinopathy
💡 Click to Reveal Answer & Nelson Rationale
The clinical scenario is characteristic of maternal Zika virus infection. **Important clues include:** Travel to an endemic region during pregnancy Maternal illness resembling a viral syndrome with rash, conjunctivitis, and arthralgia Fetal microcephaly, which was the hallmark finding during the 2015 Brazilian outbreak Zika virus infection during pregnancy is associated with a spectrum of adverse fetal outcomes,** including:** Fetal loss Central nervous system abnormalities, particularly microcephaly Contractures (arthrogryposis) Chorioretinal atrophy The disease is transmitted primarily through mosquito bites and less commonly through the sexual route. Pigmentary retinopathy is not listed among the characteristic fetal abnormalities associated with congenital Zika infection in the provided description.
- (A) Transplacental transmission during pregnancy
- (B) Transmission through breast milk
- (C) Horizontal transmission from infected caregivers after birth
- (D) Transmission through infected amniotic fluid during labor
💡 Click to Reveal Answer & Nelson Rationale
Vertical transmission of SARS-CoV-2 from mother to infant appears to be uncommon. Most studies have reported COVID-negative neonates born to infected mothers, with an almost complete absence of virus in the cord blood, amniotic fluid, and placenta. The most likely route of neonatal infection is horizontal transmission after birth, including transmission from the mother or other caregivers. **Several observations support this:** Lack of mother–neonate separation after birth is associated with an increased risk of neonatal COVID-19 infection (OR 4.94). Breastfeeding is not associated with an increased risk of neonatal infection (OR 0.35). Most infected pregnant women are asymptomatic and identified through screening at the time of delivery. Therefore, postnatal caregiver-to-infant transmission is considered the predominant mode of neonatal acquisition.
- (A) Detection of specific IgG antibodies
- (B) DNA PCR of nasopharyngeal secretions
- (C) Culture of urine
- (D) RNA PCR of plasma if mother not treated
💡 Click to Reveal Answer & Nelson Rationale
This neonate has classical manifestations of congenital rubella infection, including cataracts, congenital heart disease (continuous machinery murmur due to PDA), thrombocytopenic purpura, hepatosplenomegaly, and microcephaly. Maternal infection during the first trimester carries the highest risk of severe fetal disease because viral disruption of organogenesis occurs during this period. The diagnostic test of choice is culture of urine. Neonates with congenital rubella infection can shed rubella virus in urine for prolonged durations after birth, making urine culture a useful confirmatory investigation. The sensitivity is moderate, expense is high, and turnaround time is prolonged, often taking several days. An important concept is distinguishing organism-specific diagnostic modalities in congenital and perinatal infections. CMV is diagnosed using PCR of urine/saliva, HSV using PCR of lesions or CSF, HBV using HBsAg detection in blood, HIV using DNA/RNA PCR assays, and rubella using urine culture. **Table 48.1. Diagnostic Techniques for Diagnosis of Perinatal Infections**** ![[b6221ef4_large_table_-_2026-06-09T164646.759_1781003831.png]] **CMV, cytomegalovirus; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HEV, hepatitis E virus; HSV, herpes simplex virus; IgM, immunoglobulin M; PCR, polymerase chain reaction; RIBA, recombinant immunoblot assay; RSV, respiratory syncytial virus; RT-PCR, reverse transcriptase PCR; VZV, varicella-zoster virus. * PCRs in general are done within a half-day but often are a send-out test to a central laboratory requiring days to ship and retrieve data.
- (A) 6 mg/kg/dose intravenously every 12 hours
- (B) 8 mg/kg/dose intravenously every 12 hours
- (C) 12 mg/kg/dose intravenously every 12 hours
- (D) 16 mg/kg/dose intravenously every 12 hours
💡 Click to Reveal Answer & Nelson Rationale
This neonate has severe symptomatic congenital cytomegalovirus (CMV) infection with CNS involvement, evidenced by seizures, ventriculomegaly, and periventricular intracranial calcifications. Antiviral therapy is indicated because treatment improves hearing and neurodevelopmental outcomes in symptomatic infants. Intravenous ganciclovir is administered at a dose of 6 mg/kg/dose every 12 hours. It is preferred in critically ill infants or in those unable to tolerate enteral medications. Once enteral feeding is tolerated, therapy is commonly transitioned to oral valganciclovir to complete the treatment course. An important adverse effect of ganciclovir is neutropenia, making serial complete blood count monitoring essential during therapy. Renal and hepatic function monitoring should also be performed.
- (A) Restricting contact with known CMV-excreting children is recommended in pregnant women with occupational toddler exposure
- (B) Pregnant women presenting with a mononucleosis-like syndrome should be assessed for CMV infection
- (C) Routine maternal CMV screening has not been adopted despite the availability of diagnostic assays
- (D) Demonstration of maternal CMV antibodies may establish prior infection
💡 Click to Reveal Answer & Nelson Rationale
Cytomegalovirus is commonly transmitted through contact with saliva and urine from young children, making toddlers an important reservoir for maternal CMV acquisition during pregnancy. The CDC recommends behavioral precautions such as hand washing after contact with diapers or oral secretions, avoiding sharing utensils and toothbrushes with children, and minimizing exposure to saliva. Pregnant women who develop a mononucleosis-like illness should be evaluated for CMV infection because primary maternal infection may result in congenital transmission. Although diagnostic assays are available and serology can document prior infection, routine maternal CMV screening has not been adopted because effective preventive interventions have not consistently demonstrated benefit and fetal prognosis remains difficult to predict. Importantly, the CDC does not recommend screening for CMV or restricting contact with CMV-excreting children in schools or daycare centers.
- (A) Obtain HSV surface culture and HSV blood PCR
- (B) Obtain CSF HSV PCR and HSV blood PCR
- (C) Obtain HSV surface culture
- (D) Obtain CSF examination, HSV PCR, Serum ALT and Platelet count
💡 Click to Reveal Answer & Nelson Rationale
The maternal history is highly suggestive of recurrent HSV infection, as evidenced by a long-standing history of genital herpes, multiple recurrences during pregnancy, and documented HSV-2 seropositivity before conception. Neonates born to mothers with recurrent HSV infection have a lower risk of neonatal HSV disease than those born to mothers with primary infection because transplacentally acquired maternal antibodies provide partial protection. However, neonatal transmission can still occur. Therefore, the recommended initial evaluation for an asymptomatic neonate born to a mother with active recurrent genital lesions consists of obtaining HSV surface cultures or PCR from multiple mucocutaneous sites along with HSV blood PCR. These investigations help identify infants with asymptomatic infection who require further evaluation and treatment. If either study is positive, additional investigations including CSF examination, CSF HSV PCR, serum ALT, and platelet count are indicated. If both studies are negative, the infant should be followed clinically for evidence of neonatal HSV disease until 6 weeks of age.
- (A) Clinical follow-up for evidence of neonatal HSV disease until 6 weeks of age
- (B) Oral acyclovir suppression therapy for 6 months; oral acyclovir suppression not required
- (C) Obtain CSF examination, HSV PCR, serum ALT, and platelet count only if the infant develops symptoms
- (D) Pre-emptive therapy for 10 days; oral acyclovir suppression not required
💡 Click to Reveal Answer & Nelson Rationale
The key feature in this scenario is the maternal history suggestive of a primary HSV infection near delivery, as evidenced by the absence of prior genital herpes, previously negative HSV serology, and development of active genital lesions shortly before birth. Neonates exposed to primary maternal HSV infection are at significantly higher risk of acquiring infection because maternal protective antibodies are absent. Therefore, even when the infant is asymptomatic and initial HSV surface and blood PCR studies are negative, occult infection cannot be excluded. In this high-risk setting, pre-emptive intravenous acyclovir therapy for 10 days is recommended. Since neonatal HSV disease has not been established, prolonged oral acyclovir suppressive therapy is not required after completion of the pre-emptive course.
- (A) Absolute neutrophil count monitoring is required during both ganciclovir therapy and oral acyclovir therapy
- (B) Absolute neutrophil count and aminotransferase monitoring are required during ganciclovir therapy, whereas absolute neutrophil count monitoring is required during oral acyclovir therapy
- (C) Absolute neutrophil count and aminotransferase monitoring are required during acyclovir therapy, whereas absolute neutrophil count monitoring is required during oral ganciclovir therapy
- (D) Absolute neutrophil count monitoring is required during ganciclovir therapy, whereas serum ALT monitoring is required during oral acyclovir suppression therapy
💡 Click to Reveal Answer & Nelson Rationale
Monitoring requirements differ between ganciclovir and acyclovir therapy. Infants receiving ganciclovir for symptomatic congenital CMV infection require monitoring of absolute neutrophil count (ANC) because neutropenia is a common adverse effect. In addition, aminotransferases should be monitored because transaminitis may occur during treatment. Infants receiving prolonged oral acyclovir suppression following neonatal HSV disease require absolute neutrophil count monitoring because prolonged acyclovir therapy may also lead to neutropenia. Understanding these distinct monitoring requirements is important when managing neonatal viral infections and is a commonly tested examination concept.
- (A) Vesicles are present in about 50-60% of infants with SEM disease
- (B) Significant morbidity can occur in these infants only if signs of disseminated disease are present at the time of diagnosis.
- (C) Infants with two or more recurrences of vesicles have an increased risk of neurologic complications
- (D) Infants with keratoconjunctivitis can develop chorioretinitis, cataracts, and retinopathy
💡 Click to Reveal Answer & Nelson Rationale
Skin, eye, and mucous membrane (SEM) disease accounts for approximately 50% of neonatal HSV infections and commonly presents with clustered vesicular lesions involving the skin, eyes, or oral mucosa. Vesicles typically appear between the sixth and ninth day of life and frequently occur on the presenting part exposed to the birth canal. Vesicles occur in approximately 90% of infants with localized mucocutaneous HSV infection and represent the hallmark clinical manifestation of SEM disease. Although SEM disease is localized and lacks evidence of disseminated infection at presentation, significant morbidity may still occur. Ocular involvement can progress beyond keratoconjunctivitis, and affected infants may subsequently develop chorioretinitis, cataracts, and retinopathy. Neurologic complications may also occur despite the absence of disseminated disease, making long-term ophthalmologic and neurologic follow-up essential.
- (A) Can take for vaginal delivery right away
- (B) Plan an elective Cesarean section after the recommended course of acyclovir
- (C) Take the case for emergency Cesarean section
- (D) Plan vaginal delivery after the course of acyclovir till 40 weeks of gestation
💡 Click to Reveal Answer & Nelson Rationale
Women with known clinical HSV disease or serologic evidence of primary or non-primary first-episode infection can be offered suppressive acyclovir near term until delivery. This strategy may reduce the occurrence of visible genital lesions at the onset of labor and thereby facilitate vaginal delivery. In women who present in labor without genital lesions or prodromal symptoms, vaginal delivery is appropriate. Although suppressive acyclovir may enable vaginal delivery, its impact on prevention of neonatal HSV disease has not been established. Therefore, management is determined by the presence or absence of lesions or prodromal symptoms at labor rather than by a prior history of HSV infection alone.
- (A) Nursery personnel with active herpetic whitlow may continue caring for newborns if gloves are worn consistently and meticulous hand hygiene is maintained
- (B) Hospital personnel with active orolabial HSV infection should avoid neonatal care even when lesions are covered and a face mask is used
- (C) Mothers with active breast HSV lesions may continue breastfeeding provided the lesions are covered and direct infant contact is avoided
- (D) Nursery personnel with active herpetic whitlow should not care for newborns because transmission may occur despite appropriate glove use
💡 Click to Reveal Answer & Nelson Rationale
Postnatal HSV transmission occurs through direct contact with infectious lesions. Therefore, infants and caregivers with HSV lesions should be managed with contact precautions, and meticulous hand hygiene should be emphasized. Hospital personnel with active orolabial HSV infection generally represent a low risk to newborns when appropriate precautions such as face masks and hand hygiene are followed. Mothers with oral HSV should wear a mask while breastfeeding, and breastfeeding should be avoided if active HSV lesions are present on the breast. The major exception to these standard preventive measures is herpetic whitlow in nursery personnel. These individuals have a high risk of viral shedding, and HSV transmission may occur despite the use of gloves. Therefore, nursery personnel with herpetic whitlow should not care for newborn infants.
- (A) Recommend therapeutic abortion because fetal anomalies have been reported in association with parvovirus B19 infection
- (B) Recommend therapeutic abortion if maternal infection occurs before 20 weeks’ gestation because the risk of congenital malformations is highest during organogenesis
- (C) Continue the pregnancy with serial ultrasonography and fetal surveillance because parvovirus B19 is unlikely to cause fetal anomalies after 20 weeks of gestation
- (D) Continue the pregnancy with serial ultrasonography and fetal surveillance because parvovirus B19 is unlikely to cause fetal anomalies despite the risk of fetal involvement
💡 Click to Reveal Answer & Nelson Rationale
Although rare case reports have described infants with fetal anomalies in association with parvovirus B19 infection, current evidence suggests that parvovirus B19 is unlikely to cause fetal congenital malformations. Therefore, maternal parvovirus infection alone is not an indication for therapeutic abortion. The major fetal complications of parvovirus B19 infection result from transplacental viral transmission leading to infection of erythroid precursors, severe fetal anemia, hydrops fetalis, myocarditis, and occasionally fetal loss. Consequently, pregnancies complicated by maternal parvovirus infection should be monitored carefully with serial ultrasonography and clinical surveillance for evidence of fetal involvement. Management should focus on fetal monitoring rather than pregnancy termination.
- (A) Exclusive replacement feeding can be given if AFASS criteria are met
- (B) Replacement feeding is preferred over breastfeeding in mothers with optimal ART adherence
- (C) Mixed feeding is less desirable than exclusive breastfeeding but preferable to complete avoidance of breastfeeding when needed
- (D) Bottle feeding or katori-spoon feeding can be used for administering replacement feeds
💡 Click to Reveal Answer & Nelson Rationale
WHO 2016 guidelines recommend that mothers living with HIV should breastfeed for at least 12 months and may continue up to 24 months or beyond while receiving adequate support for ART adherence. However, if a mother decides not to breastfeed despite appropriate counseling, exclusive replacement feeding may be offered provided the AFASS (Affordable, Feasible, Acceptable, Sustainable, and Safe) criteria are fulfilled. Commercial infant formula may then be used as replacement feeding. Replacement feeds should be administered using a katori-spoon, and bottle feeding should be avoided. Although exclusive breastfeeding remains the preferred feeding strategy in mothers receiving ART, mixed feeding is considered better than complete avoidance of breastfeeding if breastfeeding cannot be exclusively maintained.
- (A) Twice-daily nevirapine started at birth and continued for 6 weeks
- (B) Twice-daily zidovudine (AZT) prophylaxis started at birth and continued for 4–6 weeks
- (C) Twice-daily zidovudine plus once-daily nevirapine started at birth and continued for 4–6 weeks
- (D) Daily zidovudine (AZT) prophylaxis started at birth and continued for 6 weeks
💡 Click to Reveal Answer & Nelson Rationale
This infant is at low risk for mother-to-child transmission (MTCT) because the mother received adequate and regular ART during pregnancy and maintained a suppressed viral load (<1000 RNA copies/mL) from 32 weeks until delivery. For infants receiving exclusive replacement feeding, neonatal prophylaxis may be given as either daily nevirapine (NVP) or twice-daily zidovudine (AZT) started at birth and continued for 4–6 weeks. Among the options provided, twice-daily AZT for 4–6 weeks is the appropriate regimen.
- (A) Perinatally infected infants typically develop symptoms within the first week of life because vertical transmission usually occurs during the second trimester
- (B) Pneumocystis jirovecii pneumonia most commonly presents during late childhood with prominent auscultatory findings
- (C) Loss of developmental milestones and diminished cognitive function are manifestations of HIV in children
- (D) Lymphadenopathy and hepatosplenomegaly occur only in advanced HIV disease and are rarely observed during infancy
💡 Click to Reveal Answer & Nelson Rationale
The clinical presentation of HIV infection differs in children compared with adults. HIV-infected newborns are usually asymptomatic, although some may present with lymphadenopathy and hepatosplenomegaly. Infants infected during the peripartum period generally do not develop signs or symptoms until after the first 2 weeks of life. Common manifestations include lymphadenopathy, hepatosplenomegaly, poor weight gain, and occasionally neuromotor abnormalities or encephalopathy. Before antiretroviral therapy became widely available, 50%–90% of HIV-infected children developed central nervous system involvement. HIV-associated encephalopathy may be clinically devastating and commonly presents with developmental delay, loss of developmental milestones, and diminished cognitive function. In addition, infants may be diagnosed with AIDS between 2 and 6 months of age when they present with Pneumocystis jirovecii pneumonia, an interstitial pneumonia that often occurs despite minimal or absent auscultatory findings.
- (A) Anti-HCV at 12 months
- (B) HCV RNA at ≥18 months
- (C) HCV RNA at 12 months
- (D) Anti-HCV at ≥18 months
💡 Click to Reveal Answer & Nelson Rationale
Infants born to mothers with HCV infection should undergo anti-HCV antibody testing at or after 18 months of age. A negative anti-HCV test at this age effectively rules out HCV infection. Although HCV RNA testing may be considered during the first year of life, the optimal timing is uncertain, and it is not the recommended routine follow-up strategy. Therefore, the preferred approach is anti-HCV testing at ≥18 months.
- (A) Joint swelling and pain
- (B) Skin thickening
- (C) Irritability
- (D) Chorioretinal atrophy
💡 Click to Reveal Answer & Nelson Rationale
The clinical scenario is suggestive of neonatal chikungunya infection. **Important clues include:** Maternal illness with fever, rash, and arthralgia Neonatal fever, irritability, rash, and joint swelling Characteristic nasal pigmentation (CHIK sign) appearing during recovery Mother-to-child transmission is most likely when maternal infection occurs in the intrapartum period, whereas the risk is low with infection remote from delivery. **Neonates with chikungunya infection may develop:** Fever Irritability Rash Joint pain and swelling Skin problems including skin thickening and other cutaneous changes Characteristic pigmentation of the nose (CHIK sign) during recovery The diagnosis in this infant is suggested by the combination of maternal peripartum febrile illness, neonatal rash and arthritis-like manifestations, and the appearance of the CHIK sign during recovery.